Draupnir Bio, a biotech company that develops effective first in class therapeutics utilizing glycans. Glycans are polymers that they play an essential role in a number of processes such as; metabolism, cellular signaling, cell-cell and microbe-host interactions. The company is able to synthesize, screen and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory and infectious diseases. The technology is currently protected by two patent applications and two additional are under preparation.
Draupnir Bio wants to take advantage of the complexity glycome and recent technological advances in the field of glycomics to become the world leading company developing innovative safe and effective glycomics-based therapies.
“We hope to benefit from the input of the NOME mentors on strategic advice regarding business strategy, as well as the prioritization of targets and clinical indications.”
Draupnir Bio’s CEO Simon Glerup and the founding team have strong expertise in protein chemistry, cell biology and business development combined with world leading expertise in carbohydrate chemistry. Draupnir Bio is located in Århus, Denmark and joined NOME in the end of 2017.